Basel, January 27, 2015 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “2014 was a transformational year for Novartis. We improved our execution, while taking steps to focus the company on our three leading businesses with global scale. We delivered solid sales growth with margin expansion, strengthened innovation, and advanced our quality and productivity agendas. I’m confident that we are positioned for future success.”

  • Net sales grew in FY 2014, with strong core[1] margin expansion
    • Net sales increased 1% (+3% cc[1 …
  • Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US
  • Biosimilar filgrastim recommended to be approved for use in all requested indications
  • Committee’s recommendation based on review of extensive data from analytical, non-clinical, clinical studies and post-marketing pharmacovigilance

Holzkirchen, January 7, 2015 – Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its …